Source: Hepatology. Unidade: FM
ABNT
OLIVEIRA, Claudia P. Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression?. Hepatology, v. 76, n. 5, p. 1246-1247, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50516. Acesso em: 11 out. 2024.APA
Oliveira, C. P. (2022). Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression? Hepatology, 76( 5), 1246-1247. doi:10.1002/hep.32510NLM
Oliveira CP. Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression? [Internet]. Hepatology. 2022 ; 76( 5): 1246-1247.[citado 2024 out. 11 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50516Vancouver
Oliveira CP. Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression? [Internet]. Hepatology. 2022 ; 76( 5): 1246-1247.[citado 2024 out. 11 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50516